Sciwind Biosciences to Highlight Positive Results for Injectable Ecnoglutide (Phase 3), Oral Ecnoglutide (Phase 1), and Novel Amylin Analogs at the American Diabetes Association (ADA) 84th Annual Conference
A Phase 1 study of oral ecnoglutide (1871-LB) showed it to be safe and well tolerated and result in pronounced weight loss (up to -6.76% after 6 weeks of dosing). Improved oral bioavailability enables a 15 to 30 mg daily dose of oral ecnoglutide to match or exceed the plasma exposure of weekly subcutaneous GLP-1 analogs for weight...
Pierre Fabre Laboratories receives the Galien International Prize for EBVALLO®, the first allogeneic immunotherapy for patients with a rare cancer
CASTRES, France, June 21, 2024 /PRNewswire/ -- Pierre Fabre Laboratories has been awarded the "Prix Galien International" Prize in the "Best Product for a Rare/Orphan Disease" category for EBVALLO® (tabelecleucel), indicated as monotherapy for the treatment of patients with post-transplant lymphoproliferative disorder positive for Epstein-Barr virus (EBV+ PTLD) who have received at least...
Biocytogen Awarded U.S. Patent for RenLite® Common Light Chain Mouse Platform
BEIJING, June 21, 2024 /PRNewswire/ -- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) announced United States Patent and Trademark Office (USPTO) patent grant for independently developed RenLite® fully human common light chain mouse platform. RenLite mice, developed using Biocytogen's proprietary Size-Unlimited and Precise Chromosome Engineering (SUPCETM) technology, feature the in situ replacement of the entire human...
ISTH Releases Evidence-Based Clinical Practice Guideline for Hemophilia Treatment
CHAPEL HILL, N.C., June 21, 2024 /PRNewswire/ -- The International Society on Thrombosis and Haemostasis (ISTH), the leading international professional medical-scientific organization dedicated to advancing the understanding, prevention, diagnosis, and treatment of conditions related to thrombosis and hemostasis, has published the first clinical practice guideline utilizing strict GRADE methodology for the treatment...
ISTH announces launch of new global education initiative in factor XI/XIa inhibition
Leading international society embarks on multi-year initiative to increase clinician awareness of factor XI/XIa inhibition BANGKOK, June 21, 2024 /PRNewswire/ -- The International Society on Thrombosis and Haemostasis (ISTH), the leading worldwide not-for-profit organization dedicated to advancing the understanding, prevention, diagnosis, and treatment of conditions related to thrombosis and hemostasis, announces the...
Ascentage Pharma Announces Closing of US$75 Million Equity Investment by Takeda
ROCKVILLE, Md. and SUZHOU, China, June 21, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that the agreed equity investment by Takeda has been closed on June 20, 2024, with all proceeds already received....
USANA Philippines Joins DSAP as its Newest Official Member
MANILA, Philippines, June 21, 2024 /PRNewswire/ -- USANA Health Sciences, Inc., a leader in global nutrition, is proud to announce that its Philippines market has been unanimously approved to become the newest member of the Direct Selling Association of the Philippines (DSAP). This is a significant achievement for the market, as it...
Tobii launches Tobii Nexus – webcam eye tracking for integration into any device or application
TAIPEI, June 20, 2024 /PRNewswire/ -- A software-only integration platform that enables eye tracking capabilities for devices with a webcam, helping developers create smarter abilities and interactivity within their applications – for any user, on any device. Tobii, the global leader in eye tracking and pioneer of attention computing, is today launching Tobii...
Keymed Biosciences Announces Safety and Efficacy Results of CM313 for Primary Immune Thrombocytopenia Published in NEJM
CHENGDU, China, June 20, 2024 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) today announced that Lei Zhang/Renchi Yang's team from the Institute of Hematology, Chinese Academy of Medical Sciences has recently published a research paper entitled "A Novel Anti-CD38 Monoclonal Antibody for Treating Immune Thrombocytopenia" in the New England Journal of Medicine. This is an investigator-initiated, single-arm, open-label phase I/II study evaluating the safety and preliminary...
Ping An Receives Five “All-Asia Executive Team 2024” Accolades From Institutional Investor Magazine
HONG KONG and SHANGHAI, June 20, 2024 /PRNewswire/ -- Institutional Investor magazine has announced the ranking of 2024 Asia (ex-Japan) Executive Team. Ping An Insurance (Group) Company of China, Ltd. (hereafter "Ping An", the "Company" or the "Group", HKEX: 2318 / 82318; SSE: 601318) is delighted to announce that its Board of Directors has been selected as the "Best Company...
